JG-98
Based on 12 publication(s) in Google Scholar
JG-98, an allosteric heat shock protein 70 (Hsp70) inhibitor, which binds tightly to a conserved site on Hsp70 and disrupts the Hsp70-Bag3 interaction. JG-98 shows anti-cancer activities affecting both cancer cells and tumor-associated macrophages.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.88%
- CAS. Nr.: 1456551-16-8
- Formel: C24H21Cl2N3OS3
- Molecular Weight:534.54
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) JG-98
More- J Control Release. 2026 May 10:393:114828. [Abstract]
- Sci Rep. 2019 Oct 7;9(1):14394. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2024 Apr 18;1871(5):119735. [Abstract]
- J Virol. 2025 Jun 5:e0050225. [Abstract]
- J Virol. 2023 Jan 31;97(1):e0126122. [Abstract]
- J Neurooncol. 2025 Jun 24. [Abstract]
- J Cell Biochem. 2022 Jan;123(1):128-141. [Abstract]
- Translational Medicine. 2025 Aug.
- bioRxiv. 2024 October 06.
- bioRxiv. 2024 August 18.
- Research Square Preprint. 2023 May 17.
- University of Groningen. 2021 May.
-
WB
Biologische Aktivität
Heat shock protein 70[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | EC50 |
0.7 μM
Compound: 30, JG-98
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24312699] |
| MCF7 | IC50 |
0.71 μM
Compound: JG-98
|
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
|
[PMID: 29953808] |
| MCF7 | IC50 |
0.71 μM
Compound: JG-98
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition
|
[PMID: 31952963] |
| MDA-MB-231 | EC50 |
0.4 μM
Compound: 30, JG-98
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24312699] |
| MDA-MB-231 | IC50 |
0.39 μM
Compound: JG-98
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 29953808] |
| MEF | EC50 |
24 μM
Compound: 30, JG-98
|
Cytotoxicity against C57BL/6 mouse MEF assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against C57BL/6 mouse MEF assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24312699] |
| MEF | IC50 |
4.2 μM
Compound: JG-98
|
Antiproliferative activity against MEF cells by MTT assay
Antiproliferative activity against MEF cells by MTT assay
|
[PMID: 29953808] |
JG-98 (30 nM-30 μM; 72 hours) has antiproliferative activity across a range of cell lines with the EC50s between ~0.3 and 4 μM[2].
JG-98 (10 μM; 48 hours) activates apoptotic mediators (cleavage of caspase-3 and PARP) in MDA-MB-231 cells[1].
JG-98 destabilizes FoxM1 and relieves suppression of downstream effectors, including p21 and p27[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7, MDA-MB-231, A375, MeWo, HeLa, HT-29, SKOV3, Jurkat, mouse embryonic fibroblasts (MEF), MM1.R, INA6, RPMI-8226, JJN-3, U266, NCI-H929, L363, MM1.S, KMS11, LP-1, AMO-1, OPM1, OPM2 cells
-
Concentration:30 nM-30 μM
-
Incubation Time:72 hours
-
Result:Active against all of the lines tested, and the EC50s were variable (between ~0.3 μM and 4 μM). Normal MEFs and OPM1 and OPM2 were relatively less sensitive.
-
Cell Line:MDA-MB-231 cells
-
Concentration:10 μM
-
Incubation Time:48 hours
-
Result:Incudes apoptotic mediators cleavage of caspase 3 and PARP.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-week-old NCR mice (xenografts of MCF7 and HeLa cells)[2]
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal injection; on days 0, 2, and 4
-
Result:Limited tumor growth, but somewhat less effectively.
Chemical Information
-
CAS. Nr. 1456551-16-8
-
Appearance Solid
-
Molecular Weight 534.54
-
Formel C24H21Cl2N3OS3
-
Color Yellow to orange
-
SMILES
CN1/C(SC2=CC(Cl)=CC=C12)=C3S/C(N(CC)C\3=O)=C\C4=[N+](C=CS4)CC5=CC=CC=C5.[Cl-]
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
J Control Release
The HSP90-dependent bioorthogonal PROTAC prodrug system enables tumor-selective and enhanced protein degradation. [Abstract]2026 May 10:393:114828. PMID: 41839264 -
Sci Rep
Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment. [Abstract]2019 Oct 7;9(1):14394. PMID: 31591429
JG-98 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2019 Oct 7;9(1):14394. [Abstract]
Western blot analysis of activated caspase-3 and cleaved PARP in cells non-treated and treated with JG-98 or VER (72 h). Representative immunoblots are shown (n = 2), actin is used as a protein loading control.
-
Biochim Biophys Acta Mol Cell Res
The human testis-enriched HSPA2 interacts with HIF-1α in epidermal keratinocytes, yet HIF-1α stability and HIF-1-dependent gene expression rely on the HSPA (HSP70) activity. [Abstract]2024 Apr 18;1871(5):119735. PMID: 38641179 -
J Virol
2025 Jun 5:e0050225. PMID: 40470959 -
J Virol
Heat Shock Protein Family A Member 1 Promotes Intracellular Amplification of Hepatitis B Virus Covalently Closed Circular DNA. [Abstract]2023 Jan 31;97(1):e0126122. PMID: 36519896 -
J Neurooncol
Glioblastoma cell motility and invasion is regulated by membrane-associated heat shock protein Hsp70. [Abstract]2025 Jun 24. PMID: 40553392 -
J Cell Biochem
Pharmacological inhibition of BAG3-HSP70 with the proposed cancer therapeutic JG-98 is toxic for cardiomyocytes. [Abstract]2022 Jan;123(1):128-141. PMID: 34487557 -
-
-
-
-
Lösungsmittel & Löslichkeit
DMSO : 5 mg/mL (9.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Li X, et al. Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med Chem Lett. 2013 Nov 14;4(11). [Content Brief]
[2]. Li X, et al. Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther. 2015 Mar;14(3):642-8. [Content Brief]
[3]. Yaglom JA, et al. Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and findingsynergistic drug combinations. Sci Rep. 2018 Feb 14;8(1):3010. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8708 mL | 9.3538 mL | 18.7077 mL | 46.7692 mL |
| 5 mM | 0.3742 mL | 1.8708 mL | 3.7415 mL | 9.3538 mL |